Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02737501
Title ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L)
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Ariad Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Brigatinib

Crizotinib

Age Groups: adult | senior
Covered Countries USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS

Additional content available in CKB BOOST